COVID-19 represented a significant challenge to cardiovascular (cV) medicine research, treatment, prevention, and, to a considerable extent, case management. The global pandemic viral infection increased the risk of thrombotic events, both venous and arterial, in a huge number of patients.
Our analysis showed that any decrease in the hospitalization of patients with AMI, especially STEMI, can substantially increase OH-CVD.